Navigation Links
Data on VIVUS' Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting

MOUNTAIN VIEW, Calif., Oct. 1 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa(TM), an investigational new drug, will be presented this Friday, October 2, 2009 at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria. This presentation follows last month's unprecedented phase 3 data for Qnexa, which demonstrated statistically significant weight loss with all three doses of Qnexa, as well as significant improvements in cardiovascular and metabolic risk factors including blood pressure, lipid levels, and blood sugar.

"This has been an exciting year for VIVUS and Qnexa. Last month, we announced pivotal phase 3 data from two year-long obesity studies, EQUIP and CONQUER, demonstrating a favorable safety profile for Qnexa as well as unprecedented weight loss, impressive glycemic control, and significant improvements in cardiovascular and metabolic risk factors," stated Leland Wilson, president and chief executive officer of VIVUS. "The enthusiasm among physicians, patients and pharmaceutical companies for a new option capable of helping patients achieve such clinically meaningful results is significant."

Wilson added, "We are also delighted that Dr. Timothy Garvey, a leading expert in metabolic disorders recognized for his research in the metabolic, molecular, and genetic pathogenesis of insulin resistance, type 2 diabetes, and obesity will present data from our previously reported phase 2 diabetes study at the EASD annual meeting. This will be the first opportunity to share this data with the European medical and pharmaceutical community."

The data being presented is from the previously announced year-long phase 2 trial (DM-230) evaluating Qnexa in patients with type 2 diabetes. The study demonstrated that Qnexa significantly reduced patients' hemoglobin A1c (HbA1c), a key indicator of blood sugar control, by 1.6% and helped patients achieve and maintain significant weight loss. The study also showed that Qnexa had a positive impact on other risk factors associated with diabetes.

"While it is widely known that type 2 diabetes can be treated through weight loss, it is well recognized that the currently approved weight loss therapies have limitations," stated Dr. Garvey MD, Professor of Medicine and Chair of the Department of Nutrition Sciences at the University of Alabama at Birmingham. "The optimal diabetes therapy will not only enable patients to control their blood sugar by lowering glucose levels to the desired range, but will also help patients achieve meaningful weight loss. The HbA1c reduction observed with Qnexa is significant, as is the percent weight loss observed, not only because of the amount, but more importantly the ability to maintain the weight loss over a year. The robust and growing body of clinical data suggests that Qnexa has the potential to play an important role in diabetes management with respect to blood sugar control and sustained weight loss."

    Following are details about the presentation:

    45th Annual Meeting of the European Association for the Study of
    Diabetes, September 30 - October 2, 2009, Messezentrum Wien, in Vienna,

    Date and Time: Friday, October 2, 2009, 12 Noon, Vienna

    Session: Novel Therapies for Type 2 Diabetes Mellitus

    Presentation Title: "Treatment with VI-0521 (Phentermine and Topiramate)
    Leads to One Year Durable Glycemic Benefit and Weight Loss in Subjects
    with Type 2 Diabetes"

    Abstract: 173

    Location: Freud Hall

    Presenter: W. Timothy Garvey, MD

About Qnexa

Qnexa (Q-NEX-uh) is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule. Qnexa, an investigational drug, is being developed to address weight loss. In phase 2 and 3 clinical data to date, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors.


VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.


    VIVUS, Inc.                Investor Relations:  The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
                               Media Relations:     Pure Communications, Inc.
                                                    Sheryl Seapy


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
2. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
3. Innovative Dental Education Initiative From Henry Schein, ADA And ADEA To Be Featured At ADA Annual Session In Hawaii
4. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
5. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
6. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
7. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
8. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
9. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
10. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
11. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
Post Your Comments:
(Date:11/24/2015)... , Nov. 25, 2015 WuXi PharmaTech (Cayman) ... a leading open-access R&D capability and technology platform company ... operations in China and ... at an extraordinary general meeting of shareholders held today, ... to authorize and approve the previously announced agreement and ...
(Date:11/24/2015)... , Nov. 24, 2015  Natera, ... in non-invasive genetic testing and the analysis ... it will present at the 27 th ... December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., ... financial results, business activities and financial outlook. ...
(Date:11/24/2015)... 24, 2015  In the pharmaceutical industry, companies want ... to quickly uncover new insights, tactics and strategies that ... --> However, organizations often find it ... and ensure that all rules and regulations are met ... major barrier to efficiently launching market research projects is ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... their knowledge and experiences at a live taping of the next CURE ... the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel & Conference ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... With Thanksgiving ... Insurance is sharing safety tips to help protect your family and vehicle. , According ... around the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety tips from ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester ... University President Carl S. Cleveland III on October 16. , “Katie is very ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Bibliomotion ... and Detroit Taught Me about Reinvention and Diversity by Nancy M. Schlichting, ... suffer, with hospitals failing to adequately address the needs of patients and their families, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... All her life, Don Peck’s mother wondered if ... obituary said she might have been. After a 25-year search for information, Don and ... whom she shared a last name. Turns out, it was Don’s father who was ...
Breaking Medicine News(10 mins):